The stream · Daily digest
The stream: Saturday, October 24, 2026
4 briefs from the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 3
-
Mitapivat shows haemoglobin response in sickle cell disease trial
In the RISE UP phase 3 trial, 56 (41%) of 138 patients on mitapivat achieved a haemoglobin response versus 2 (3%) of 69 on placebo, an adjusted difference of 38% (95% CI 29-47). The annualised rate of pain crises was 2·6 for mitapivat and 3·1 for placebo (p=0·1213).
Source: PubMed record of a Phase III journal article, October 23, 2026
-
Nivolumab plus relatlimab plus chemo vs nivolumab plus chemo in NSCLC
The authors reported that the primary endpoint of objective response rate was not met (51.3% versus 45.0%). In the PD-L1 ≥1% nonsquamous subgroup, a trend toward improved clinical benefit was seen (ORR 58.0% versus 39.6%; PFS HR 0.68).
Source: PubMed record of a Phase III journal article, October 23, 2026
-
Lilly reports 79% response rate for Sofe-M in platinum-sensitive ovarian cancer
The Phase 1 study of sofetabart mipitecan (Sofe-M) plus bevacizumab in 29 patients with measurable disease reported a confirmed objective response rate of 79.3% (23/29) and a disease control rate of 100%. The most common grade ≥3 adverse events were neutropenia (42%) and anemia (24%), with 6% of patients discontinuing treatment due to an adverse event.
Source: Company press release (PR Newswire), October 24, 2026
Regulation · 1
-
FDA issues priority review voucher for ISEMBYLD (apitegromab-mstn)
The FDA announced the issuance of a priority review voucher to the sponsor of ISEMBYLD (apitegromab-mstn), approved September 11, 2026. The voucher is awarded because the product meets the criteria for rare pediatric disease applications under the FD&C Act.
Source: Federal Register notice, October 26, 2026